Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 8월 2022 - 5:05AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that, effective on August 15, 2022, the
Compensation Committee of its Board of Directors granted
non-qualified stock options to purchase an aggregate of 70,000
shares of its common stock and restricted stock units (RSUs)
covering an aggregate of 70,000 shares of its common stock to two
new employees under Personalis’ 2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee,
or non-employee director, of Personalis, as an inducement material
to such individual’s entering into employment with Personalis,
pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis
is making this announcement as required by Nasdaq rules.
The inducement stock options have an exercise price of $5.32 per
share, which is equal to the closing price of Personalis’ common
stock on August 15, 2022, and will vest over four years, with 25%
of the shares vesting on the first anniversary of the grant date
and 1/36th of the remaining shares vesting monthly thereafter,
subject to continued service through each applicable vesting date.
The RSUs will vest over four years, with 25% of the shares vesting
on the first anniversary of the grant date and an additional 25% of
the shares vesting annually thereafter, subject to continued
service through each applicable vesting date. The options and RSUs
are subject to the terms and conditions of Personalis’ 2020
Inducement Plan, and the terms and conditions of the applicable
award agreement covering each grant.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale, and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220816005667/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Temple
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024